Difference between revisions of "Category:Protein expression-specific medications"
Jump to navigation
Jump to search
(Created page with "Category:Biomarker-specific medications") |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| + | Drugs with a regulatory indication for effectiveness (or lack of efficacy) in the context of one or more measurable protein expression patterns (including the absence of a protein expression, e.g., triple-negative breast cancer). This also includes mismatch repair deficient (dMMR) indications. | ||
| + | |||
[[Category:Biomarker-specific medications]] | [[Category:Biomarker-specific medications]] | ||
Latest revision as of 00:29, 15 June 2024
Drugs with a regulatory indication for effectiveness (or lack of efficacy) in the context of one or more measurable protein expression patterns (including the absence of a protein expression, e.g., triple-negative breast cancer). This also includes mismatch repair deficient (dMMR) indications.
Pages in category "Protein expression-specific medications"
The following 49 pages are in this category, out of 49 total.
P
R
T
- Tamoxifen (Nolvadex)
- Toremifene (Fareston)
- Tositumomab and I-131 (Bexxar)
- Trastuzumab (Herceptin)
- Trastuzumab and hyaluronidase (Herceptin Hylecta)
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab emtansine (Kadcyla)
- Trastuzumab-anns (Kanjinti)
- Trastuzumab-dkst (Ogivri)
- Trastuzumab-dttb (Ontruzant)
- Trastuzumab-pkrb (Herzuma)
- Trastuzumab-qyyp (Trazimera)
- Trastuzumab-strf (Hercessi)
- Tucatinib (Tukysa)